课题基金 / 基金详情

ANTI TNF CHIMERIC MONOCLONAL ANTIBODY IN ACUTE RHEUMATOID ARTHRITIS

ANTI TNF CHIMERIC MONOCLONAL ANTIBODY IN ACUTE RHEUMATOID ARTHRITIS
抗 TNF 嵌合单克隆抗体治疗急性类风湿性关节炎
批准号:
6118037
负责人:
MICHAEL H WEISMAN
金额:
$1.46万
依托单位国家:
美国
项目类别:
财政年份:
1998
资助国家:
美国
项目状态:
已结题
起止时间:
1998-12-01 至 1999-11-30

项目摘要

项目成果

MICHAEL H WEISMAN的其他基金

相关文献

中文摘要
翻译
评估cA2联合甲氨蝶呤治疗活动性类风湿关节炎患者的安全性、有效性和慢性治疗,尽管用甲氨蝶呤治疗。在治疗开始一年后,评估疾病体征和症状的减少、残疾的减少、关节损伤的延缓、疾病缓解和生活质量的改善。
英文摘要
Evaluate safety and efficacy and chronic treatment with cA2 in combination with methotrexate in patients with active rheumatoid arthritis despite treatment with methotrexate. Evaluate the reduction is signs and symptoms of disease, reduction in disability, retardation of joint damage, disease remission and quality of life improvement at one year following onset of treatment.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
RECOMBINANT HUMAN INTERLEUKIN ELEVEN IN RHEUMATOID ARTHRITIS
STUDY OF ORAL CCII IN TREATMENT OF ACTIVE RHEUMATOID ARTHRITIS
INDUCTION COURSE & MAINTENANCE CYCLE OF AG4263 IN RHEUMATOID ARTHRITIS
LJP 394 ADMINISTERED TO PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS